These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 30015065)

  • 21. Glucose-Lowering Medications and Angina Burden in Patients with Stable Coronary Disease: results from the Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina (TERISA) Trial.
    Arnold SV; McGuire DK; Spertus JA; Tang F; Yue P; Inzucchi SE; Belardinelli L; Chaitman BR; Kosiborod M
    Am Heart J; 2015 Oct; 170(4):753-759.e2. PubMed ID: 26386799
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry.
    Becher PM; Schrage B; Ferrannini G; Benson L; Butler J; Carrero JJ; Cosentino F; Dahlström U; Mellbin L; Rosano GMC; Sinagra G; Stolfo D; Lund LH; Savarese G
    Eur J Heart Fail; 2021 Jun; 23(6):1012-1022. PubMed ID: 33599357
    [TBL] [Abstract][Full Text] [Related]  

  • 23. GLP-1 receptor agonists and heart failure in diabetes.
    Scheen AJ
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S13-2S19. PubMed ID: 28431666
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cardiovascular safety of glucose-lowering agents as add-on medication to metformin treatment in type 2 diabetes: report from the Swedish National Diabetes Register.
    Ekström N; Svensson AM; Miftaraj M; Franzén S; Zethelius B; Eliasson B; Gudbjörnsdottir S
    Diabetes Obes Metab; 2016 Oct; 18(10):990-8. PubMed ID: 27282621
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical impact of oral antidiabetic medications in heart failure patients.
    Palazzuoli A; Ceccarelli E; Ruocco G; Nuti R
    Heart Fail Rev; 2018 May; 23(3):325-335. PubMed ID: 29359260
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of glucose-lowering therapies on risk of stroke in type 2 diabetes.
    Bonnet F; Scheen AJ
    Diabetes Metab; 2017 Sep; 43(4):299-313. PubMed ID: 28522196
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Type 2 diabetes mellitus and heart failure: a position statement from the Heart Failure Association of the European Society of Cardiology.
    Seferović PM; Petrie MC; Filippatos GS; Anker SD; Rosano G; Bauersachs J; Paulus WJ; Komajda M; Cosentino F; de Boer RA; Farmakis D; Doehner W; Lambrinou E; Lopatin Y; Piepoli MF; Theodorakis MJ; Wiggers H; Lekakis J; Mebazaa A; Mamas MA; Tschöpe C; Hoes AW; Seferović JP; Logue J; McDonagh T; Riley JP; Milinković I; Polovina M; van Veldhuisen DJ; Lainscak M; Maggioni AP; Ruschitzka F; McMurray JJV
    Eur J Heart Fail; 2018 May; 20(5):853-872. PubMed ID: 29520964
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The influence of metformin and the presence of type 2 diabetes mellitus on mortality and hospitalisation in patients with heart failure.
    Retwiński A; Kosmalski M; Crespo-Leiro M; Maggioni A; Opolski G; Ponikowski P; Poloński L; Jankowska E; Drzewoski J; Drożdż J
    Kardiol Pol; 2018; 76(9):1336-1343. PubMed ID: 29862487
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A comprehensive population-based characterization of heart failure with mid-range ejection fraction.
    Koh AS; Tay WT; Teng THK; Vedin O; Benson L; Dahlstrom U; Savarese G; Lam CSP; Lund LH
    Eur J Heart Fail; 2017 Dec; 19(12):1624-1634. PubMed ID: 28948683
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of empagliflozin in patients with diabetes and heart failure.
    Pham D; Albuquerque Rocha N; McGuire DK; Neeland IJ
    Trends Cardiovasc Med; 2017 Feb; 27(2):144-151. PubMed ID: 27612553
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Trends and site-level variation of novel cardiovascular medication utilization among patients admitted for heart failure or coronary artery disease in the US Veterans Affairs System: 2017-2021.
    Salahuddin T; Hebbe A; Daus M; Essien UR; Waldo SW; Rodriguez F; Ho PM; Simons C; Gilmartin HM; Doll JA
    Am Heart J; 2024 Feb; 268():68-79. PubMed ID: 37956920
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Database.
    Fadini GP; Avogaro A; Degli Esposti L; Russo P; Saragoni S; Buda S; Rosano G; Pecorelli S; Pani L;
    Eur Heart J; 2015 Sep; 36(36):2454-62. PubMed ID: 26112890
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Exploration of the clinical benefits of sodium glucose co-transporter 2 inhibitors in diabetic patients with concomitant heart failure.
    Tanaka A; Node K
    Cardiovasc Diabetol; 2018 May; 17(1):74. PubMed ID: 29801492
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metformin and SGLT2i as First-line Combination Therapy in Type 2 Diabetes: A Real-world Study With a Focus on Ethnicity.
    Anson M; Zhao SS; Essa H; Austin P; Ibarburu GH; Lip GYH; Alam U
    Clin Ther; 2023 Dec; 45(12):1259-1265. PubMed ID: 37648574
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence and incidence of heart failure in type 2 diabetes patients: results from a nationwide prospective cohort-the DIABET-IC study.
    Gonzalez-Manzanares R; Anguita-Gámez M; Muñiz J; Barrios V; Gimeno-Orna JA; Pérez A; Rodríguez-Padial L; Anguita M;
    Cardiovasc Diabetol; 2024 Jul; 23(1):253. PubMed ID: 39014420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The entero-insular axis: implications for human metabolism.
    Ranganath LR
    Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
    [TBL] [Abstract][Full Text] [Related]  

  • 37. EMPA-REG and Other Cardiovascular Outcome Trials of Glucose-lowering Agents: Implications for Future Treatment Strategies in Type 2 Diabetes Mellitus.
    Schernthaner G; Schernthaner-Reiter MH; Schernthaner GH
    Clin Ther; 2016 Jun; 38(6):1288-1298. PubMed ID: 27210264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Heart Failure in Type 2 Diabetes Mellitus.
    Kenny HC; Abel ED
    Circ Res; 2019 Jan; 124(1):121-141. PubMed ID: 30605420
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of Atherosclerotic Cardiovascular Disease, Heart Failure, and Chronic Kidney Disease in Patients with Type 2 Diabetes Mellitus: A Primary Care Research Network-based Study.
    Goderis G; Vaes B; Mamouris P; van Craeyveld E; Mathieu C
    Exp Clin Endocrinol Diabetes; 2022 Jul; 130(7):447-453. PubMed ID: 34154020
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Intensive glycemic control has no impact on the risk of heart failure in type 2 diabetic patients: evidence from a 37,229 patient meta-analysis.
    Castagno D; Baird-Gunning J; Jhund PS; Biondi-Zoccai G; MacDonald MR; Petrie MC; Gaita F; McMurray JJ
    Am Heart J; 2011 Nov; 162(5):938-948.e2. PubMed ID: 22093212
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.